Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ShionogiFRA:SH0 +0.14%80 Debt-to-Equity is 0.39 as of Jun. 2026, which is 3800% above its 10-year median of 0.01. GuruFocus rates FRA:SH0 with a GF Score™ of 80/100 and a GF Value™ of €16.79 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 812 Drug Manufacturers companies, Shionogi ranks worse than 60.59% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Shionogi's Debt-to-Equity or its related term are showing as below:
FRA:SH0'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.41
Current: 0.39
During the past 13 years, the highest Debt-to-Equity Ratio of Shionogi was 0.41. The lowest was 0.00. And the median was 0.01.
FRA:SH0's Debt-to-Equity is ranked worse than 60.59% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs FRA:SH0: 0.39
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Shionogi Debt-to-Equity Related Terms
Shionogi Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Shionogi's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shionogi's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shionogi Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shionogi's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Shionogi's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shionogi (FRA:SH0) has a Debt-to-Equity of 0.39 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Shionogi and its competitors. This is 3800% above median its historical median of 0.01. According to the industry distribution chart, Shionogi ranks #492 out of 812 companies in the Drug Manufacturers industry, placing it in the top 60.6%.
Is Shionogi's Debt-to-Equity too high?
Shionogi's current Debt-to-Equity of 0.39 is 3800% above median its 10-year median of 0.01. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Shionogi's value of 0.39 is 44.4% above this industry median. Based on the distribution chart, Shionogi ranks #492 out of 812 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shionogi has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shionogi's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shionogi ranks #492 out of 812 companies for Debt-to-Equity. This places Shionogi in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Shionogi's value of 0.39 is 44.4% above this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.27, Shionogi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shionogi's current Debt-to-Equity of 0.39 is 44.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Shionogi and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shionogi's current Debt-to-Equity is 0.39, which is 3800% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shionogi stock overvalued right now?
Based on GuruFocus' analysis, Shionogi (FRA:SH0) is currently considered Modestly Undervalued. The stock's GF Value™ is €16.79, compared to a current price of €14.65 — trading 12.7% below its estimated fair value. The current Debt-to-Equity is 0.39, which is 3800% above median its 10-year median of 0.01 and 44.4% above the Drug Manufacturers industry median of 0.27. Shionogi's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Shionogi (FRA:SH0), the current Debt-to-Equity is 0.39 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shionogi (FRA:SH0) Overvalued in 2026?
Based on GuruFocus' analysis, Shionogi stock appears to be undervalued.
The current stock price of €14.65 is trading 12.7% below its estimated GF Value™ of €16.79.
GuruFocus considers Shionogi to be Modestly Undervalued.
Key valuation signals for FRA:SH0:
Debt-to-Equity: 0.39 (3800% above median its 10-year median of 0.01)
GF Value™: €16.79 vs. price of €14.65 (12.7% below fair value)
Industry Position: 44.4% above the Drug Manufacturers median (#492 of 812)
No single metric tells the full story. See the FRA:SH0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shionogi & Co Ltd is a specialty and generic drug manufacturing company. The company focuses on the manufacturing and distribution of pharmaceuticals, diagnostic reagents, and medical devices. The company engages in manufacturing, formulation, packaging, and analysis as part of its commercialization research that spans late-stage drug discovery through commercial production. It provides products and services in Japan, Europe, North America, and other regions.
80GF Score
Get the complete analysis for FRA:SH0
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:SH0 has been successfully added to your 
